Stuart Poulton - Jan 24, 2024 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role: EVP, Chief Development Officer
Signature: /s/Nancy Smith as Attorney-in-Fact for Stuart Poulton
Stock symbol: KPTI
Transactions as of: Jan 24, 2024
Transactions value $: $0
Form type: 4
Date filed: 1/25/2024, 07:14 PM
Previous filing: Aug 1, 2023
Next filing: Feb 20, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KPTI	Common Stock	Award	$0	+13.3K	+8.53%	$0.00	170K	Jan 24, 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2023 that have been earned based on the level of achievement of a certain clinical milestone, as certified by the issuer's compensation committee on January 24, 2024. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs will vest on February 28, 2024, the first anniversary of the grant date, subject to continued employment through such vesting date.

Content

Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2023 that have been earned based on the level of achievement of a certain clinical milestone, as certified by the issuer's compensation committee on January 24, 2024. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs will vest on February 28, 2024, the first anniversary of the grant date, subject to continued employment through such vesting date.